Sources: GitLab is letting employees sell equity in a secondary share sale that values the company over $6B, up from a valuation of $2.7B in September 2019
- GitLab competes with GitHub, which Microsoft acquired in 2018 for $7.5 billion. — The company had originally aimed to go public …
Context & Ripple Effects
GitLab's employee secondary at over $6B more than doubles its September 2019 valuation of $2.7B, and lands against a fixed benchmark: Microsoft paid $7.5B for its rival GitHub competitor GitHub back in 2018. The company had originally aimed to go public, and this sale functions as a liquidity bridge while that path stays open.
First-order effects
- Employees gain a way to cash out part of their equity before any listing, converting paper gains into cash at a valuation that has roughly doubled in about fourteen months.
- The $6B mark puts GitLab within striking distance of Microsoft's $7.5B price for GitHub, sharpening its negotiating position with investors and potential acquirers.
Second-order effects
- The secondary effectively pre-markets an IPO: weeks later GitLab confirmed it was considering going public on the strength of that $6B valuation and revenue growth, and by October it filed to raise up to $624M targeting ~$9B.
- Microsoft's GitHub now faces a better-capitalized independent rival whose employees are financially locked in through a listing rather than an acquisition exit.
Third-order effects
- If the pattern holds, large secondaries become the standard mechanism for late-stage startups to retain talent without an exit — a structural answer to the private valuation–liquidity gap that reshapes when and why companies go public.
- Developer-tooling consolidation continues on both tracks: GitLab ultimately listed at a $14.9B debut market cap, and by 2024 was exploring a sale to peers like Datadog — showing secondaries can precede either an IPO or strategic acquisition.
The trend: Late-stage software companies are using employee secondary sales as a deliberate bridge asset — setting a public-market reference price before choosing between an IPO and a strategic sale.